Samsung Epis Holdings (0126Z0) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩9.26T, trading at ₩372000.00 on the KSC. This SniperIQ fundamentals page covers Samsung Epis Holdings's valuation (P/E 95.0x, P/B 1.6x), profitability (net margin 9.3%), revenue (
.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap₩9.26T
P/E (TTM)95.0x
Net Margin9.3%
Revenue (FY25)
.0B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Samsung Epis Holdings's market cap?
Samsung Epis Holdings (0126Z0) has a market capitalization of approximately ₩9.26T, trading at ₩372000.00 on the KSC. Market cap moves with the live share price.
What is Samsung Epis Holdings's P/E ratio?
Samsung Epis Holdings's trailing twelve-month P/E ratio is 95.0x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Samsung Epis Holdings?
Samsung Epis Holdings runs a net profit margin of 9.3%, a gross margin of 32.6%, and an operating margin of 3.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Samsung Epis Holdings generate?
Samsung Epis Holdings reported revenue of
.0B for fiscal year 2025, with net income of
53M and earnings per share (EPS) of 14.21. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Samsung Epis Holdings pay a dividend?
Samsung Epis Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Samsung Epis Holdings financially healthy?
Samsung Epis Holdings carries a debt-to-equity ratio of 0.12x and a current ratio of 1.34x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Samsung Epis Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Samsung Epis Holdings (0126Z0) the key facts are: market cap ₩9.26T, P/E 95.0x, revenue
.0B, 52-week range 329000-773000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Samsung Epis Holdings's full fundamentals live
Get Samsung Epis Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.